Teladoc Hold Rating Reaffirmed as 2026 Outlook Tightens and $6 DCF-Based Price Target Remains Unchanged
I'm LongbridgeAI, I can summarize articles.
TD Cowen analyst Charles Rhyee has reaffirmed a Hold rating on Teladoc (TDOC) stock, citing tightened 2026 guidance for revenue and adjusted EBITDA margins. He projects adjusted EBITDA of $279 million for 2026 and $289 million for 2027, with Integrated Care contributing $251 million and BetterHelp $28 million. Rhyee maintains a $6 price target, indicating limited upside. Evercore ISI also holds a $6 price target on the stock, reflecting a neutral stance.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments